tradingkey.logo
tradingkey.logo
Search

Exact Sciences Corp

EXAS
Add to Watchlist
104.910USD
0.0000.00%
Close 06/29, 16:00ETQuotes delayed by 15 min
20.03BMarket Cap
LossP/E TTM

More Details of Exact Sciences Corp Company

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp Info

Ticker SymbolEXAS
Company nameExact Sciences Corp
IPO dateJan 30, 2001
CEOConroy (Kevin T)
Number of employees6900
Security typeOrdinary Share
Fiscal year-endJan 30
Address5505 Endeavor Lane
CityMADISON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code53719
Phone16082845700
Websitehttps://www.exactsciences.com/
Ticker SymbolEXAS
IPO dateJan 30, 2001
CEOConroy (Kevin T)

Company Executives of Exact Sciences Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%

FAQs

Who are the top five shareholders of Exact Sciences Corp?

The top five shareholders of Exact Sciences Corp are: Mr. Kevin T. Conroy

How many institutions hold shares of Exact Sciences Corp (EXAS)?

As of 2026Q1, 1452 institutions hold shares of Exact Sciences Corp, with a combined market value of approximately 147.12M, accounting for 77.07% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -48700001.00.

What is the biggest source of revenue for Exact Sciences Corp?

In 2026Q1, the Commercial business generated the highest revenue for Exact Sciences Corp, amounting to 1.52B and accounting for 46.79% of total revenue.
KeyAI